Back to Search
ABBY BRODIE, D.M.D.
D.M.D.
Dentist
NPI: 1770690927Individual
Specialties, Licenses & Credentials
DentistPrimary
Dentist
Code: 122300000X
DN12869(FL)
Research & Publications (20)
Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
PMID 19190349·Cancer Res·2009
7-preclinical
History of aromatase: saga of an important biological mediator and therapeutic target.
PMID 19389994·Endocr Rev·2009
6-review
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
PMID 19244107·Cancer Res·2009
7-preclinical
Epidermal growth factor variations in amniotic membrane used for ex vivo tissue constructs.
PMID 19196134·Tissue Eng Part A·2009
8-other
17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.
PMID 18790763·Mol Cancer Ther·2008
7-preclinical
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro.
PMID 18202015·Mol Cancer Ther·2008
8-other
Metal-metal communication in copper(II) complexes of cyclotetraphosphazene ligands.
PMID 18817378·Inorg Chem·2008
8-other
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
PMID 18451180·Cancer Res·2008
7-preclinical
Stopping treatment can reverse acquired resistance to letrozole.
PMID 18559495·Cancer Res·2008
7-preclinical
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
PMID 18723482·Mol Cancer Ther·2008
8-other
Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors.
PMID 18072255·Cancer·2008
7-preclinical
Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model.
PMID 17942301·J Steroid Biochem Mol Biol·2008
7-preclinical
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
PMID 18072254·Cancer·2008
8-other
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
PMID 18695261·Oncologist·2008
6-review
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
PMID 17473209·Clin Cancer Res·2007
7-preclinical
Conformational flexibility in 2,2'-Dioxybiphenyl-chloro-cyclotetraphosphazenes and its relevance to polyphosphazene analogues.
PMID 17335275·Inorg Chem·2007
8-other
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
PMID 17387344·Br J Cancer·2007
7-preclinical
Conformationally rigid chelate rings in metal complexes of pyridyloxy-substituted 2,2'-dioxybiphenyl-cyclotetra- and cyclotriphosphazene platforms.
PMID 17949082·Inorg Chem·2007
8-other
Does a high UV environment ensure adequate vitamin D status?
PMID 17964181·J Photochem Photobiol B·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3200 S UNIVERSITY DR
DAVIE, FL 33328 - Phone
- (954) 262-7342
Quick Facts
- NPI
- 1770690927
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile